1. Isobe, T., Naiki, T., Sugiyama, Y., Naiki-Ito, A., Nagai, T., Etani, T., Iida, K., Noda, Y., Shimizu, N., Aoki, M., Gonda, M., Morikawa, T., Banno, R., Kubota, H., Ando, R., Kawai, N., Yasui, T.: Experience and prognostic analysis with avelumab switch maintenance treatment in metastatic urothelial carcinoma. Oncology,103:11-21, 2025.
2. Ahmed, O.H.M., Naiki-Ito, A., Takahashi, S., Alexander, W.T., Alexander, D.B., Tsuda, H.: A review of the carcinogenic potential of thick rigid and thin flexible multi-walled carbon nanotubes in the lung. Nanomaterials, 15:168, 2025.
3. Yanase, T., Naiki, T., Naiki-Ito, A., Okawa, R., Niwa, S., Shimizu, N., Hamamoto, S., Fujii, Y., Takahashi, H., Yasui, T.: Efficacy of prostatectomy using a Retzius-sparing approach as an additional excision in anal canal carcinoma after brachytherapy for prostate adenocarcinoma. IJU Case Rep, 8:174-178, 2025
4. Naiki-Ito, A., Naiki, T., Takahashi, S.: Exploring experimental models of prostate cancer in chemoprevention: Oxidative stress as a key pathway to translational research. Pathol Int, 75:131-144, 2025.
5. Matsumoto, N., Wanifuchi-Endo Y., Fujita, T., Asano, T., Terada, M., Nozawa, K., Mori, M., Isogai, A., Niwa, Y., Kato, H., Komura, M., Toyama, T.: Prognosis, clinicopathological characteristics, and treatment patterns of patients with ER-intermediate-positive breast cancer undergoing long-term follow-up. ESMO Open, 10 :104508, 2025.
6. Nukui, T., Shimura, T., Inaguma, S., Sugimura, N., Fukusada, S., Nishigaki, R., Kojima, Y., Kanno, T., Sasaki, M., Tanaka, M., Ozeki, K., Kubota, E., Takahashi, S., Kataoka, H.: Pathological resection depth in cold snare polypectomy and underwater endoscopic mucosal resection for superficial nonampullary duodenal epithelial tumors. Dig Dis, 43:273-279, 2025.
7. Wang, W., Kumegawa, K., Chapman, O., Shiraishi, R., Xiao, Z., Okonechnikov, K., Sun, Y., Pfister, S.M., Feng, W., Uesaka, N., Hoshino, M., Takahashi, S., Korshunov, A., Chavez, L., Maruyama, R., Kawauchi, D.: Chromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progression. Cell Rep, 44:115673, 2025.
8. Naiki, T., Naiki-Ito, A., Murakami, A., Kato, H., Sugiyama, Y., Kawai, T., Kato, S., Etani, T., Nagai, T., Shimizu, N., Morikawa, T., Aoki, M., Gonda, M., Kuang, X., Nagayasu, Y., Hamamoto, S., Yasui, T., Takahashi, S.: Preliminary evidence on safety and clinical efficacy of luteolin for patients with prostate cancer under active surveillance. Prostate Cancer, in press.
9. Kuang, X., Naiki-Ito, A., Kawamura H., Murakami, A., Komura, M., Kato, H., Nagayasu, Y., Takahashi, S.: Hepatic stellate cell inhibition by angiotensin II receptor blocker mitigates liver injury and fibrosis via NF-kB-galectin-3 suppression in a rat non-alcoholic steatohepatitis model. Arch Toxicol, in press.
10. Isogai, A., Terada, M., Wanifuchi-Endo, Y., Fujita, T., Asano, T., Mori, M., Nozawa, K., Matsumoto, N., Niwa, Y., Tanaka, Y., Kato, H., Komura, M., Toyama, T.: Optimal patient population for adjuvant S-1 therapy in hormone receptor-positive, HER2-negative early breast cancer. Breast Cancer, in press.